Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Operating Expenses (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Operating Expenses for 10 consecutive years, with $104.3 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 25.55% to $104.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $381.8 million through Dec 2025, down 3.5% year-over-year, with the annual reading at $381.8 million for FY2025, 3.5% down from the prior year.
  • Operating Expenses for Q4 2025 was $104.3 million at Rhythm Pharmaceuticals, roughly flat from $104.0 million in the prior quarter.
  • The five-year high for Operating Expenses was $165.9 million in Q1 2024, with the low at $34.4 million in Q1 2021.
  • Average Operating Expenses over 5 years is $70.8 million, with a median of $65.7 million recorded in 2023.
  • The sharpest move saw Operating Expenses surged 159.15% in 2024, then crashed 51.94% in 2025.
  • Over 5 years, Operating Expenses stood at $52.8 million in 2021, then fell by 3.62% to $50.9 million in 2022, then increased by 28.7% to $65.5 million in 2023, then increased by 26.85% to $83.1 million in 2024, then increased by 25.55% to $104.3 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $104.3 million, $104.0 million, and $93.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.